<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39337090</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Interaction of Complement and Intrinsic Coagulation System: A Comparative Study between COVID-19 and Bacterial Sepsis Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5603</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13185603</ELocationID><Abstract><AbstractText><b>Background/Objectives</b>: Through the past several years, a constant interaction has been implicated between complement and coagulation cascades. SARS-CoV-2 infection and bacterial sepsis are potent activators of both cascades. This study aims to compare the extent of complement and intrinsic coagulation pathway activation (and the interplay between them) among patients with COVID-19 and bacterial sepsis. <b>Methods</b>: Serum and plasma samples were collected from 25 ICU patients (11 patients with COVID-19 and 14 patients with bacterial sepsis) at two time points (on admission and either on improvement or deterioration). The activities of coagulation factors XI and XII and complement factors C3a and C5a were measured at both time points. <b>Results</b>: The activities of factors XI and XII were increased in both groups of patients and at both time points. However, there were no statistically significant differences between SARS-CoV-2 and bacterial sepsis patients. On the other hand, both C3a and C5a were significantly higher in the COVID-19 group on admission. This correlation was preserved on reassessment. <b>Conclusions</b>: Complement activation seems to be more enhanced in COVID-19 than bacterial sepsis. However, the lack of statistical significance in factors XI and XII indicates t the presence of additional pathways for complement activation in SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papadakis</LastName><ForeName>Dimitrios-Dorotheos</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0003-4422-1262</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Politou</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Haematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittaras</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Haematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stergiou</LastName><ForeName>Ioanna E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koutsoukou</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1536-3205</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, First Department of Respiratory Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 115 27 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kompoti</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thriassio General Hospital of Eleusis, 190 18 Eleusis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasileiadis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9529-9361</Identifier><AffiliationInfo><Affiliation>1st Critical Care Department, Evangelismos Hospital, National and Kapodistrian University of Athens, 115 21 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coagulation</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">thromboinflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337090</ArticleId><ArticleId IdType="pmc">PMC11432620</ArticleId><ArticleId IdType="doi">10.3390/jcm13185603</ArticleId><ArticleId IdType="pii">jcm13185603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pryzdial E.L.G., Leatherdale A., Conway E.M. Coagulation and complement: Key innate defense participants in a seamless web. Front. Immunol. 2022;13:918775. doi: 10.3389/fimmu.2022.918775.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.918775</ArticleId><ArticleId IdType="pmc">PMC9398469</ArticleId><ArticleId IdType="pubmed">36016942</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurich M., McCluskey G. Complement and coagulation crosstalk—Factor H in the spotlight. Immunobiology. 2023;228:152707. doi: 10.1016/j.imbio.2023.152707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2023.152707</ArticleId><ArticleId IdType="pubmed">37633063</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., NiCheallaigh C., Bergin C., Martin-Loeches I., Browne P., Bacon C.L., Gaule R., Gillett A., Byrne M., et al. COVID-19 coagulopathy in Caucasian patients. Br. J. Haematol. 2020;189:1044–1049. doi: 10.1111/bjh.16749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16749</ArticleId><ArticleId IdType="pmc">PMC7264579</ArticleId><ArticleId IdType="pubmed">32330308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Yalavarthi S., Shi H., Gockman K., Zuo M., Madison J.A., Blair C., Weber A., Barnes B.J., Egeblad M., et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:e138999. doi: 10.1172/jci.insight.138999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B., Noris M., Lambrecht B.N., Kemper C. The state of complement in COVID-19. Nat. Rev. Immunol. 2022;22:77–84. doi: 10.1038/s41577-021-00665-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId><ArticleId IdType="pmc">PMC8672651</ArticleId><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Maneta E., Aivalioti E., Tual-Chalot S., Emini Veseli B., Gatsiou A., Stamatelopoulos K., Stellos K. Endothelial dysfunction and immunothrombosis in sepsis. Front. Immunol. 2023;14:1144229. doi: 10.3389/fimmu.2023.1144229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1144229</ArticleId><ArticleId IdType="pmc">PMC10110956</ArticleId><ArticleId IdType="pubmed">37081895</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupu F., Keshari R.S., Lambris J.D., Coggeshall K.M. Crosstalk between the coagulation and complement systems in sepsis. Thromb. Res. 2014;133((Suppl. S1)):S28–S31. doi: 10.1016/j.thromres.2014.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.03.014</ArticleId><ArticleId IdType="pmc">PMC4154483</ArticleId><ArticleId IdType="pubmed">24759136</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: A severity of disease classification system. Crit. Care Med. 1985;13:818–829. doi: 10.1097/00003246-198510000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198510000-00009</ArticleId><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., Reinhart C.K., Suter P.M., Thijs L.G. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiadis I., Politou M., Dimopoulos S., Rovina N., Kyriakopoulou M., Kyriakoudi A., Tripodaki E.S., Koutsouri T., Terpos E., Koulouris N., et al. Variation of endothelium-related hemostatic factors during sepsis. Microcirculation. 2018;25:e12500. doi: 10.1111/micc.12500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/micc.12500</ArticleId><ArticleId IdType="pubmed">30159948</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadakis D.D., Politou M., Kompoti M., Vagionas D., Kostakou E., Theodoulou D., Kaniaris E., Rovina N., Panayiotakopoulos G., Dimopoulos S., et al. ImmunostimulationandCoagulopathyinCOVID-19 Comparedto Patients with H1N1 Pneumonia or Bacterial Sepsis. In Vivo. 2022;36:954–960. doi: 10.21873/invivo.12786.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.12786</ArticleId><ArticleId IdType="pmc">PMC8931926</ArticleId><ArticleId IdType="pubmed">35241555</ArticleId></ArticleIdList></Reference><Reference><Citation>Charchaflieh J., Wei J., Labaze G., Hou Y.J., Babarsh B., Stutz H., Lee H., Worah S., Zhang M. The role of complement system in septic shock. Clin. Dev. Immunol. 2012;2012:407324. doi: 10.1155/2012/407324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/407324</ArticleId><ArticleId IdType="pmc">PMC3459296</ArticleId><ArticleId IdType="pubmed">23049598</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumestre-Pérard C., Doerr E., Colomb M.G., Loos M. Involvement of complement pathways in patients with bacterial septicemia. Mol. Immunol. 2007;44:1631–1638. doi: 10.1016/j.molimm.2006.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2006.08.008</ArticleId><ArticleId IdType="pubmed">17049606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim E.H.T., van Amstel R.B.E., de Boer V.V., van Vught L.A., de Bruin S., Brouwer M.C., Vlaar A.P.J., van de Beek D. Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Rev. 2023;57:100995. doi: 10.1016/j.blre.2022.100995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.100995</ArticleId><ArticleId IdType="pmc">PMC9338830</ArticleId><ArticleId IdType="pubmed">35934552</ArticleId></ArticleIdList></Reference><Reference><Citation>Diurno F., Numis F.G., Porta G., Cirillo F., Maddaluno S., Ragozzino A., De Negri P., Di Gennaro C., Pagano A., Allegorico E., et al. Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience. Eur. Rev. Med. Pharmacol. Sci. 2020;24:4040–4047. doi: 10.26355/eurrev_202004_20875.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202004_20875</ArticleId><ArticleId IdType="pubmed">32329881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggenenti P., Di Marco F., Cortinovis M., Lorini L., Sala S., Novelli L., Raimondi F., Gastoldi S., Galbusera M., Donadelli R., et al. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS ONE. 2021;16:e0261113. doi: 10.1371/journal.pone.0261113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261113</ArticleId><ArticleId IdType="pmc">PMC8687582</ArticleId><ArticleId IdType="pubmed">34928990</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D., Heming N., Grimaldi-Bensouda L., Frémeaux-Bacchi V., Vigan M., Roux A.L., Marchal A., Michelon H., Rottman M., Moine P. Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine. 2020;28:100590. doi: 10.1016/j.eclinm.2020.100590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100590</ArticleId><ArticleId IdType="pmc">PMC7644240</ArticleId><ArticleId IdType="pubmed">33173853</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C., Brüningk S.C., Hoch T., Fan B., Muzio G., Thompson R.C., Ceglarek L., Meledin R., Westermann P., Emmenegger M., et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024;383:eadg7942. doi: 10.1126/science.adg7942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber G., Pan X.Z., Ranjan N., Warmack A., Brodsky R. Pathogenicity of SARS-CoV-2 Spike Protein Variants Correlates with Coagulation and Complement Assays. Blood. 2022;140((Suppl. S1)):2705–2706. doi: 10.1182/blood-2022-169738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-169738</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan V., Zilberman-Rudenko J., Olson S.R., Lupu F., McCarty O.J.T., Shatzel J.J. The contact pathway and sepsis. Res. Pract. Thromb. Haemost. 2019;3:331–339. doi: 10.1002/rth2.12217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12217</ArticleId><ArticleId IdType="pmc">PMC6611366</ArticleId><ArticleId IdType="pubmed">31294319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor-Cohen R., Zucker M., Grissom C., Brown S.M., Seligsohn U., Campbell R.A., Blair A.M., Rondina M.T. The reduced form of coagulation factor XI is associated with illness severity and coagulopathy in critically-ill septic patients. J. Thromb. Thrombolysis. 2019;47:186–191. doi: 10.1007/s11239-018-1797-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1797-9</ArticleId><ArticleId IdType="pmc">PMC6393197</ArticleId><ArticleId IdType="pubmed">30600428</ArticleId></ArticleIdList></Reference><Reference><Citation>Silasi R., Keshari R.S., Regmi G., Lupu C., Georgescu C., Simmons J.H., Wallisch M., Kohs T.C., Shatzel J.J., Olson S.R., et al. Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus. Blood. 2021;138:178–189. doi: 10.1182/blood.2020009345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020009345</ArticleId><ArticleId IdType="pmc">PMC8288658</ArticleId><ArticleId IdType="pubmed">33598692</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroo I., Zeerleder S., Ding C., Luken B.M., Roelofs J.J.T.H., de Boer O.J., Meijers J.C.M., Castellino F.J., van ‘t Veer C., van der Poll T. Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. ThrombHaemost. 2017;117:1601–1614. doi: 10.1160/TH16-12-0920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-12-0920</ArticleId><ArticleId IdType="pubmed">28492700</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker E.I., Verbout N.G., Leung P.Y., Hurst S., McCarty O.J., Gailani D., Gruber A. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood. 2012;119:4762–4768. doi: 10.1182/blood-2011-10-386185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-10-386185</ArticleId><ArticleId IdType="pmc">PMC3367876</ArticleId><ArticleId IdType="pubmed">22442348</ArticleId></ArticleIdList></Reference><Reference><Citation>Silasi R., Keshari R.S., Lupu C., Van Rensburg W.J., Chaaban H., Regmi G., Shamanaev A., Shatzel J.J., Puy C., Lorentz C.U., et al. Inhibition of contact-mediated activation of factor XI protects baboons against S. aureus-induced organ damage and death. Blood Adv. 2019;3:658–669. doi: 10.1182/bloodadvances.2018029983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018029983</ArticleId><ArticleId IdType="pmc">PMC6391670</ArticleId><ArticleId IdType="pubmed">30808684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bane CEJr Ivanov I., Matafonov A., Boyd K.L., Cheng Q., Sherwood E.R., Tucker E.I., Smiley S.T., McCarty O.J., Gruber A., Gailani D. Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice. PLoS ONE. 2016;11:e0152968. doi: 10.1371/journal.pone.0152968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152968</ArticleId><ArticleId IdType="pmc">PMC4821616</ArticleId><ArticleId IdType="pubmed">27046148</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D., Szaba F.M., Kummer L.W., Johnson L.L., Tucker E.I., Gruber A., Gailani D. Smiley ST.2012.Factor XI-Deficient Mice Display Reduced Inflammation, Coagulopathy, and Bacterial Growth during Listeriosis. Infect. Immun. 2012;80:91–99. doi: 10.1128/IAI.05568-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.05568-11</ArticleId><ArticleId IdType="pmc">PMC3255681</ArticleId><ArticleId IdType="pubmed">22006565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Mishra A., Ashraf Z. COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection. TH Open. 2022;6:e70–e79. doi: 10.1055/s-0042-1744185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0042-1744185</ArticleId><ArticleId IdType="pmc">PMC8913175</ArticleId><ArticleId IdType="pubmed">35280973</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson M.W., Lima F., Moraes C.R.P., Ilich A., Huber S.C., Barbosa M.S., Santos I., Palma A.C., Nunes T.A., Ulaf R.G., et al. Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Adv. 2022;6:3367–3377. doi: 10.1182/bloodadvances.2021006620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006620</ArticleId><ArticleId IdType="pmc">PMC8893951</ArticleId><ArticleId IdType="pubmed">35235941</ArticleId></ArticleIdList></Reference><Reference><Citation>Englert H., Rangaswamy C., Deppermann C., Sperhake J.P., Krisp C., Schreier D., Gordon E., Konrath S., Haddad M., Pula G., et al. Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine. 2021;67:103382. doi: 10.1016/j.ebiom.2021.103382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103382</ArticleId><ArticleId IdType="pmc">PMC8120108</ArticleId><ArticleId IdType="pubmed">34000623</ArticleId></ArticleIdList></Reference><Reference><Citation>Papi A., Stapleton R.D., Shore P.M., Bica M.A., Chen Y., Larbig M., Welte T. Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19. Lung. 2023;201:159–170. doi: 10.1007/s00408-023-00615-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-023-00615-9</ArticleId><ArticleId IdType="pmc">PMC10064633</ArticleId><ArticleId IdType="pubmed">37000214</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson O., Mohlin C., Nilsson B., Ekdahl K.N. The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System. Front. Immunol. 2019;10:1590. doi: 10.3389/fimmu.2019.01590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01590</ArticleId><ArticleId IdType="pmc">PMC6635567</ArticleId><ArticleId IdType="pubmed">31354729</ArticleId></ArticleIdList></Reference><Reference><Citation>deNooijer A.H., Kotsaki A., Kranidioti E., Kox M., Pickkers P., Toonen E.J.M., Giamarellos-Bourboulis E.J., Netea M.G. Complement activation in severely ill patients with sepsis: No relationship with inflammation and disease severity. Crit. Care. 2023;27:63. doi: 10.1186/s13054-023-04344-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04344-6</ArticleId><ArticleId IdType="pmc">PMC9933299</ArticleId><ArticleId IdType="pubmed">36797757</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos T.A., Oliveira J.E., Fonseca C.D.D., Barbosa D.A. Belasco AGDS, Miura CRM. Sepsis and COVID-19: Outcomes in young adults in intensive care. Rev. Bras. Enferm. 2023;76:e20230037. doi: 10.1590/0034-7167-2023-0037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0034-7167-2023-0037</ArticleId><ArticleId IdType="pmc">PMC10695060</ArticleId><ArticleId IdType="pubmed">38055486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>